Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Historical Holders from Q1 2021 to Q3 2025

Symbol
CGEM on Nasdaq
CUSIP
230031106
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
58.8M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
61.1M
Holdings value
$362M
% of all portfolios
0.002%
Grand Portfolio weight change
0%
Number of holders
141
Number of buys
81
Number of sells
-62
Average Value change %
0%
Average buys %
+0%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynx1 Capital Management LP 14.5% +100% $50.7M $24.6M 8.55M +94.3% Lynx1 Capital Management LP Oct 8, 2025
VANGUARD GROUP INC 4.98% $17.5M 2.94M The Vanguard Group Sep 30, 2025
Flynn James E 4.95% $17.4M 2.93M Deerfield Mgmt, L.P. Sep 30, 2025
FRANKLIN RESOURCES INC 3.8% $16.4M 2.19M Franklin Resources, Inc. Sep 30, 2024
CITADEL ADVISORS LLC 3.4% -34% $11.8M -$6.05M 1.99M -33.9% Kenneth Griffin Sep 30, 2025

Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 61.1M $362M -$12.5M $5.93 141
2025 Q2 62.6M $471M -$15.6M $7.53 141
2025 Q1 64.7M $490M -$25.8M $7.57 145
2024 Q4 65.6M $799M -$43.3M $12.18 144
2024 Q3 65M $1.09B -$1.27M $16.74 136
2024 Q2 62.9M $1.1B +$234M $17.44 134
2024 Q1 2.65M $45.2M -$9.75M $17.04 8
2023 Q4 10.1K $103K -$7.06K $10.19 1
2023 Q3 38M $344M +$11M $9.05 104
2023 Q2 36.7M $395M +$48.7M $10.76 102
2023 Q1 32.2M $329M -$56.4M $10.23 96
2022 Q4 37.7M $398M +$5.32M $10.55 92
2022 Q3 36.7M $471M -$6.34M $12.82 90
2022 Q2 36.9M $473M +$22.1M $12.82 76
2022 Q1 36.8M $385M +$4.83M $10.47 74
2021 Q4 36M $554M +$2.28M $15.43 72
2021 Q3 33.9M $762M +$33.7M $22.57 64
2021 Q2 32.3M $829M -$17.6M $25.75 70
2021 Q1 31.3M $1.3B +$1.3B $41.67 70